GEO-CM01 / GeoVax, BravoVax - LARVOL DELTA

Design and Evaluation of MVA-Vectored Universal Beta coronavirus Vaccines (VACCINES SUMMIT 2022) - No abstract available

Infectious Disease • Novel Coronavirus Disease

GeoVax Labs, Inc. (BIO 2022) - "In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors."

Head and Neck Cancer • Hematological Disorders • Infectious Disease • Malaria • Novel Coronavirus Disease • Oncology • Solid Tumor

GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire, GeoVax, Inc.) - "We are pleased with the progress of our three vaccine candidates for COVID-19. Safety, efficacy, and durability of protection (long-lasting) are the expected characteristics of our GV-MVA-VLP™ vaccine platform being used for constructing our vaccines....We will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy....We plan to then proceed directly to manufacturing and initial human clinical testing for safety and immunogenicity....We expect BravoVax to provide testing and manufacturing support, as well as direct interactions with Chinese authorities, for a parallel regulatory pathway to what we will pursue in the United States. We have initiated discussions and submitted applications with U.S. funding agencies as well."

Clinical • Commercial • Licensing / partnership • Infectious Disease • Novel Coronavirus Disease

"@bradloncar talk to Geovax, they have a big pipeline of vaccines including covid19" (@Severin48997729)

Infectious Disease • Novel Coronavirus Disease

GeoVax progresses in coronavirus (COVID-19) vaccine development program (GlobeNewswire) - "GeoVax Labs, Inc....provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLP^TM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China."

Clinical